Univariate analysis of potential risk factors for patients with persistent or recurrent disease, n
| Clinical data | Recurrence group (n=30) | Control group (n=35) | χ2 | P |
|---|---|---|---|---|
| Age (years) | 0.032 | 0.857 | ||
| ≤35 | 3 (10.0) | 2 (5.7) | ||
| >35 | 27 (90.0) | 33 (94.3) | ||
| Stage | 2.681 | 0.262 | ||
| IB | 3 (10.0) | 1 (2.9) | ||
| II | 18 (60.0) | 27 (77.1) | ||
| III | 9 (30.0) | 7 (20.0) | ||
| Tumor size (cm) | 0.707 | 0.401 | ||
| ≤4 | 21 (70.0) | 21 (60.0) | ||
| >4 | 9 (30.0) | 14 (40.0) | ||
| Lymph node | 19.726 | <0.001 | ||
| Positive | 20 (66.7) | 5 (16.7) | ||
| Negative | 10 (33.3) | 30 (83.3) | ||
| SCCAg (ng/mL) | 7.05 | 0.005 | ||
| ≤10 | 16 (53.3) | 7 (20.0) | ||
| >10 | 14 (46.6) | 28 (80.0) | ||
| Radiation time (d) | 0 | 1 | ||
| ≤56 | 26 (86.7) | 31 (88.6) | ||
| >56 | 4 (13.3) | 4 (11.4) | ||
| Radiation dose (Gy) | — | 0.495 | ||
| ≤86 | 30 (100) | 33 (94.3) | ||
| <86 | 0 (0) | 2 (5.7) | ||
| Cycles of chemotherapy | 0.372 | 0.542 | ||
| ≤4 | 24 (80.0) | 31 (88.6) | ||
| <4 | 6 (20.0) | 4 (11.4) | ||